Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

Harbord, Marcus; Eliakim, Rami; Bettenworth, Dominik; Karmiris, Konstantinos; Κατσάνος, Κωνσταντίνος; Kopylov, Uri; Kucharzik, Torsten; Molnár, Tamás; Raine, Tim; Sebastian, Shaji; Sousa, Helena Tavares de; Dignaß, Axel; Carbonnel, Franck

doi:10.1093/ecco-jcc/jjx105

Cited by 43 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 46 , 47 ] According to the latest European Crohn and Colitis Organization guidelines if C difficile is detected in IBD patients, oral vancomycin should be administered, fecal microbial transplant considered, and immunosuppressive therapy should be stopped if possible, although this may not always be warranted. [ 48 ] Infection with C difficile may intensify the severity of IBD or even trigger IBD flare, [ 15 ] underscoring the importance of antibiotic therapy. [ 46 ] By contrast, intensifying IBD treatment may worsen the outcome of IBD patients with concomitant CDI.…”

Section: Discussionmentioning

confidence: 99%

Clostridium difficile infection in hospitalized patients with inflammatory bowel disease

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Clostridium difficile infection in hospitalized patients with inflammatory bowel disease

et al. 2018

View full text Add to dashboard Cite

show abstract

“…So far, the treatment of IBD includes induction therapy and maintenance therapy (10,11). Traditional therapeutic drugs include amino salicylates, glucocorticoid (GC), immunosuppressive (such as azathioprine methotrexate), and TNF-α monoclonal antibodies (12).…”

Section: Introductionmentioning

confidence: 99%

Serum Biomarkers for Inflammatory Bowel Disease

et al. 2020

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic, inflammatory disorder of the gastrointestinal tract. As the novel therapeutic goal and biologicals are widely recognized, accurate assessment of disease and prediction of therapeutic response have become a crucial challenge in clinical practice. Also, because of the continuously rising incidence, convenient and economical methods of diagnosis and clinical assessment are urgently needed. Recently, serum biomarkers have made a great progress and become a focus in IBD study because they are non-invasive, convenient, and relatively inexpensive than are markers in biopsy tissue, stool, breath, and other body fluids. Aims: To review the available data on serological biomarkers for IBD. Methods: We searched PubMed using predefined key words on relevant literatures of serum biomarkers regarding diagnosis, evaluation of therapeutic efficacy, surveillance of disease activity, and assessment of prognosis for IBD. Results: We reviewed serological biomarkers that are well-established and widely used (e.g., C-reactive protein), newly discovered biomarkers (e.g., cytokines, antibodies, and non-coding RNAs), and also recently advancements in serological biomarkers (e.g., metabolomics and proteomics) that are used in different aspects of IBD management. Conclusions: With such a wealth of researches, to date, there are still no ideal serum biomarkers for IBD. Serum profiling and non-coding RNAs are just starting to blossom but reveal great promise for future clinical practice. Combining different biomarkers can be valuable in improving performance of disease evaluation.

show abstract

“…The cause of IBD is still unknown, so there is no known cure and the current goal of treatment is maintenance of remission [11][12][13]. For many years, IBD was treated with 5-aminosalicylic acid (5-ASA) drugs, steroids (prednisone), and thiopurine immunomodulators (azathioprine and 6-mercaptopurine).…”

Section: Introductionmentioning

confidence: 99%

Drug Lag for Inflammatory Bowel Disease Treatments in the East and West

Okabayashi

Hibi²

2018

Inflamm Intest Dis

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD), though historically common in the West, is now increasingly prevalent in industrializing countries. A simultaneous dramatic increase in IBD drug options has enabled most patients to achieve remission. Nevertheless, worldwide disparities in the approval of IBD drugs, or “drug lag”, remain problematic. Summary: Drug lag for major IBD drugs before March 31, 2018 (12 for Crohn’s disease [CD] and 13 for ulcerative colitis [UC]) was compared between that of the United States (US), European Union (EU), and Asia (Japan, China, South Korea, Taiwan, and the Philippines) to assess current trends. In the US, unapproved IBD drugs accounted for 16.7% (2/12) for CD and 23.1% (3/13) for UC; approval lag was 3.8 (0–80.5) months for CD and 3.6 (0–88) months for UC. In the EU, unapproved drugs accounted for 16.7% (2/12) for CD and 15.4% (2/13) for UC; approval lag was 0.03 (0–13.9) months for CD and 0 (0–13.9) months for UC. This demonstrates the short drug lag in both regions, although one drug developed in a joint US/EU clinical trial had around a 350-day approval lag. In Asia, the proportion of unapproved IBD drugs was the lowest in Japan at 33.3% (4/12) for CD and 23.1% (3/13) for UC; South Korea had the shortest lag for CD at 13.2 (0–133.1) months and the Philippines had the shortest lag for UC at 9.9 (0.6–176.2) months, but these countries still had longer lag periods than the West. However, a proportion of unapproved drugs and approval lag has decreased considerably in Asia since the start of the biologics era. Key Messages: Despite the recent shortening drug lag between different countries and regions, this study shows that disparities persist. With globalization, eliminating these disparate drug lags is necessary to manage IBD and may require efforts toward international adoption of a more standardized approval process.

show abstract

Corrigendum: Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management

Cited by 43 publications

References 0 publications

Clostridium difficile infection in hospitalized patients with inflammatory bowel disease

Clostridium difficile infection in hospitalized patients with inflammatory bowel disease

Serum Biomarkers for Inflammatory Bowel Disease

Drug Lag for Inflammatory Bowel Disease Treatments in the East and West

Contact Info

Product

Resources

About